Posts by: Forest Ray PhD

Forest Ray PhD

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

March 26, 2021March 26, 2021

Swimming, Hydrotherapy Improve Functional Capacity, Study Shows

News

Both swimming and hydrotherapy can improve functional capacity in hemophilia patients, according to data from a recent study. Of those two types of aquatic exercises, however, hydrotherapy was associated with ... Read more

February 22, 2021February 22, 2021

Posture Exercises May Improve Joint Health in Children

News

Exercises to control posture could improve joint health in children with hemophilia and should form part of regular rehabilitation programs, a study suggests. The balance disturbances uncovered in the study ... Read more

February 1, 2021February 1, 2021

Immunoadsorption May Be Useful Add-on Therapy in Acquired Hemophilia

News

Immunoadsorption, or the selective removal of antibodies from the blood, might prove useful as an add-on treatment for patients with acquired hemophilia, according to a recent study. If confirmed, this ... Read more

January 27, 2021January 27, 2021

Great Attention Needed in Care of Women and Girls With Hemophilia

News

Although hemophilia treatments are generally effective, women and girls with this disease have specific medical challenges, such as excessive menstrual bleeding, that must be addressed for better clinical care. A study evaluated the ... Read more

January 26, 2021January 26, 2021

COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say

News, syndicated

The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to ... Read more

December 9, 2020December 9, 2020

UniQure Shares Long-term Data About AMT-061 and AMT-060 Gene Therapy Candidates

News

Two potential gene therapies — AMT-060 and AMT-061 (etranacogene dezaparvovec) — lead to safe and long-term increases in factor IX (FIX) activity, as well as fewer bleeds among patients with ... Read more

December 7, 2020December 7, 2020

MarzAA on FDA Fast Track to Treat Hemophilia A or B With Inhibitors

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to marzeptacog alfa activated (MarzAA), a lab-made version of clotting factor VIIa for the subcutaneous (under-the-skin) treatment of ... Read more

October 28, 2020October 28, 2020

Patients Report Mostly High Satisfaction With US Hemophilia Treatment Centers

News

People living with bleeding disorders such as hemophilia and von Willebrand disease report consistently high levels of satisfaction with the care they receive at U.S. hemophilia treatment centers (HTCs), according ... Read more

October 19, 2020October 26, 2020

Hemlibra ‘Comparable or Better’ Treatment for Hemophilia A, ICER Finds

News

At standard U.S. doses, Hemlibra (emicizumab) provides comparable or even superior clinical benefits than prophylactic factor VIII (FVIII) replacement therapy among adults with severe hemophilia A and no inhibitors, according to a ... Read more

October 16, 2020October 16, 2020

Alprolix Shows Key Benefits for Hemophilia B Patients in Real-World Setting

News

Treatment with Alprolix improves bleeding control, reduces the need for infusions, and improves patient compliance among people with hemophilia B, according to a review of real-world data. The study, “Real‐world data ... Read more